Amgen Reports 58% Lower Death Hazard in Lung Cancer Trial

Your call?🐂 Bullish🐻 Bearish

58%

lower death hazard

Median overall survival was 21.1 months with tarlatamab and durvalumab, compared with 12.7 months with durvalumab alone. The trial tested the combination as maintenance therapy after initial treatment.